Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group[J]. Ann Oncol, 2004, 15(1):104.
[2]
Chen S, Paruligiani G. Meta—analysis of BRCAl and BRCA2 penetrance[J]. J Clin Oneol, 2007, 25(11):1329-1333.
[3]
Verma S, Joy AA, Rayson D, et al. HER story: the next chapter in HER-2-directed therapy for advanced breast cancer[J]. Oncologist, 2013, 18(11):1153-1166.
[4]
Giordano SH, Temin S, Kirshner JJ, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2014, 32(19):2078-2099.
[5]
Verri E, Guglielmini P, Puntoni M, et al. NER2/neu oncoprotein overexpression in epitheliaI ovarian cancer: evaluation of its prevalence and prognosticsignificance[J]. Oncology, 2005, 68:154-161.
[6]
Riener EK, Arnold N, Kommoss F, et al. The prognostic and predictive valw of immunohistochemically detected,Her-2 overexpression in 361 patients with ovarian cancer;a multicenter study[J]. Gynecol Oncol, 2004, 95(1):89.
[7]
Lesnock JL, Darcy KM, Tian C, et al. BRCAl expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study[J]. Br J Cancer, 2013, 108(6):1231-1237.
[8]
Vollebergh MA, Lips EH, Nederlof PM, et al. Genomic patterns resembling BRCAl-and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy[J]. Breast Cancer Res, 2014, 16(3):R47.
[9]
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCAl or BRCA2 mutations detected in case series unselected for family history: a combined analysis of22 studies[J]. Am J Hum Genet, 2003, 72(5):1117- 1130.
[10]
李向东.C-erbB-2、ER和PR在乳腺癌中的表达与预后意义[J].现代肿瘤医学,2006,14(3):289. LI Xiangdong. Expression and prognostic significance of C-erbB-2, ER and PR in breast cancer[J]. Modern Oncology Medicine, 2006, 14(3):289.
[11]
Koyama T, Mikami Y, Saga T, et al. Secondary ovarian tumors: spectrum of CT and MR features with pathologic correlation[J]. Abdom Imaging, 2007, 32(6):784-795.
[12]
Wolff EF, Martel M, Gwin K, et al. Synchronous primary breast and ovarian cancer with ovarian cancer metastases to a breast sentinel lymph node[J]. Breast J, 2009, 15(2):203-205.
[13]
Sandor V, Reed E, Sarosy G, et al. Synchronous inflammatory breast cancer and advanced ovarian carcinoma: a case with prolonged disease—free survival[J]. Ann Oncol, 1999, 10(5): 585-588.
[14]
何以丰,徐丛剑,冯令达.HER2与上皮性卵巢癌术后生存率相关性的Meta分析[J].中国循证医学杂志,2007,7(6):420. HE Yifeng, XU Congjian, FENG Lingda. Meta analysis of the correlation between HER2 and the survival rate of epithelial ovarian cancer[J]. Chinese Journal of Evidence-based Medicine, 2007, 7(6):420.
